214 related articles for article (PubMed ID: 31851090)
21. Value of Preoperative Systemic Immune-Inflammation Index and Albumin-Bilirubin Grade in Patients with Hepatocellular Carcinoma Undergoing Transarterial Embolization.
Ha F; Wang X; Han T; Jia K; Wang S; Song D
Turk J Gastroenterol; 2023 Apr; 34(4):413-420. PubMed ID: 36620927
[TBL] [Abstract][Full Text] [Related]
22. Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization.
Kim JH; Sinn DH; Lee JH; Hyun D; Cho SK; Shin SW; Chang Y; Kim YJ; Yoon JH; Kang W; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Choi MS
Dig Dis Sci; 2018 Apr; 63(4):1062-1071. PubMed ID: 29442276
[TBL] [Abstract][Full Text] [Related]
23. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
Kim DY; Han KH
Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
[TBL] [Abstract][Full Text] [Related]
24. Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort.
Adhoute X; Pénaranda G; Raoul JL; Pietri O; Bronowicki JP; Castellani P; Perrier H; Monnet O; Bayle O; Oules V; Pol B; Beaurain P; Muller C; Cassagneau P; Bourlière M
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1414-1423. PubMed ID: 31045613
[TBL] [Abstract][Full Text] [Related]
25. Pre-operative transarterial chemoembolization for resectable hepatocellular carcinoma adversely affects post-operative patient outcome.
Kim IS; Lim YS; Lee HC; Suh DJ; Lee YJ; Lee SG
Aliment Pharmacol Ther; 2008 Feb; 27(4):338-45. PubMed ID: 18047564
[TBL] [Abstract][Full Text] [Related]
26. Transarterial chemoembolization for treatment of hepatocellular carcinoma: A single center experience.
Idilman I; Peynircioğlu B; Cil BE; Doğanay Erdoğan B; Yalçın S; Bayraktar Y; Kav T; Altundağ K; Balkancı F
Turk J Gastroenterol; 2013; 24(2):141-7. PubMed ID: 23934461
[TBL] [Abstract][Full Text] [Related]
27. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
[TBL] [Abstract][Full Text] [Related]
28. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival.
Grieco A; Marcoccia S; Miele L; Marmiroli L; Caminiti G; Ragazzoni E; Cotroneo AR; Cefaro GA; Rapaccini GL; Gasbarrini G
Hepatogastroenterology; 2003; 50(49):207-12. PubMed ID: 12630024
[TBL] [Abstract][Full Text] [Related]
29. Transarterial chemoembolization and radioembolization.
Sangro B; Salem R
Semin Liver Dis; 2014 Nov; 34(4):435-43. PubMed ID: 25369305
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
31. A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients.
Chen L; Ni CF; Chen SX; Cao JM; Zhu HD; Guo JH; Zhu GY; Zhong BY; Ding W; He SC; Deng G; Teng GJ
J Vasc Interv Radiol; 2016 Sep; 27(9):1288-1297. PubMed ID: 27013402
[TBL] [Abstract][Full Text] [Related]
32. A prediction model for liver abscess developing after transarterial chemoembolization in patients with hepatocellular carcinoma.
Shin JU; Kim KM; Shin SW; Min SY; Park SU; Sinn DH; Gwak GY; Choi MS; Lee JH; Paik SW; Yoo BC; Koh KC
Dig Liver Dis; 2014 Sep; 46(9):813-7. PubMed ID: 24881853
[TBL] [Abstract][Full Text] [Related]
33. Does Preoperative Transarterial Chemoembolization for Hepatocellular Carcinoma Increase the Incidence of Hepatic Artery Thrombosis After Living-Donor Liver Transplant?
Ince V; Ersan V; Karakas S; Kutluturk K; Karadag N; Kutlu R; Yilmaz S
Exp Clin Transplant; 2017 Mar; 15(Suppl 2):21-24. PubMed ID: 28301994
[TBL] [Abstract][Full Text] [Related]
34. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.
Adhoute X; Pénaranda G; Raoul JL; Bollon E; Pol B; Letreut YP; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Hardwigsen J; Lefolgoc G; Castellani P; Bronowicki JP; Bourlière M
Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):706-715. PubMed ID: 28195873
[TBL] [Abstract][Full Text] [Related]
35. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
36. Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
Ni JY; Fang ZT; An C; Sun HL; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
Int J Hyperthermia; 2019; 36(1):841-853. PubMed ID: 31452408
[No Abstract] [Full Text] [Related]
37. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Cho YK; Chung JW; Kim JK; Ahn YS; Kim MY; Park YO; Kim WT; Byun JH
Cancer; 2008 Jan; 112(2):352-61. PubMed ID: 18008352
[TBL] [Abstract][Full Text] [Related]
38. Hepatocellular carcinoma with internal mammary artery supply: feasibility and efficacy of transarterial chemoembolization and factors affecting patient prognosis.
Kim HC; Chung JW; Choi SH; Yoon JH; Lee HS; Jae HJ; Lee W; Park JH
J Vasc Interv Radiol; 2007 May; 18(5):611-9; quiz 620. PubMed ID: 17494842
[TBL] [Abstract][Full Text] [Related]
39. Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma.
Labeur TA; Takkenberg RB; Klümpen HJ; van Delden OM
Cardiovasc Intervent Radiol; 2019 Feb; 42(2):230-238. PubMed ID: 30488302
[TBL] [Abstract][Full Text] [Related]
40. Neutrophil-lymphocyte ratio predicts the therapeutic benefit of neoadjuvant transarterial chemoembolization in patients with resectable hepatocellular carcinoma.
Hong YM; Cho M; Yoon KT; Ryu JH; Yang KH; Jeon UB; Hwang TH
Eur J Gastroenterol Hepatol; 2020 Sep; 32(9):1186-1191. PubMed ID: 31851089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
